Pathological Alteration in the Choroid Plexus of Alzheimer’s Disease: Implication for New Therapy Approaches by Agnieszka Krzyzanowska & Eva Carro
MINI REVIEW ARTICLE
published: 03 May 2012
doi: 10.3389/fphar.2012.00075
Pathological alteration in the choroid plexus of Alzheimer’s
disease: implication for new therapy approaches
Agnieszka Krzyzanowska1,2 and Eva Carro1,2*
1 Neuroscience Group, Instituto de Investigacion Hospital 12 de Octubre (i+12), Madrid, Spain
2 Biomedical Research Networking Center in Neurodegenerative Diseases, Madrid, Spain
Edited by:
Joana A. Palha, University of Minho,
Portugal
Reviewed by:
Jason B. Wu, Cedars-Sinai Medical
Center, USA
Catarina Oliveira, CNC-Center for
Neuroscience, Portugal
*Correspondence:
Eva Carro, Neuroscience Group,
Instituto de Investigacion Hospital 12
de Octubre (i+12), Avenue de
Córdoba s/n, 28041 Madrid, Spain.
e-mail: carroeva@h120.es
Morphological alterations of choroid plexus in Alzheimer’s disease (AD) have been exten-
sively investigated. These changes include epithelial atrophy, thickening of the basement
membrane, and stroma ﬁbrosis. As a result, synthesis, secretory, and transportation func-
tions are signiﬁcantly altered resulting in decreased cerebrospinal ﬂuid (CSF) turnover.
Recent studies discuss the potential impacts of these changes, including the possibility of
reduced resistance to stress insults and slow clearance of toxic compounds from CSF with
speciﬁc reference to the amyloid peptide. Here, we review new evidences for AD-related
changes in the choroid plexus. The data suggest that the signiﬁcantly altered functions of
the choroid plexus contribute to the multiparametric pathogenesis of late-onset AD.
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INTRODUCTION
In the recent years, much attention has been directed to the roles
of the choroid plexus in the central nervous system (CNS) under
both normal andpathological conditions. This specialized ventric-
ular structure has recently emerged as a key player in a variety of
processes that monitor and maintain the biochemical and cellular
homeostasis of the CNS.
Themain role of the choroid plexus is to produce cerebrospinal
ﬂuid (CSF) and to maintain the extracellular environment of the
brain by monitoring the chemical exchange between the CSF and
the brain tissue. This involves the surveying of the chemical and
immunological status of the extracellular ﬂuid and the removal
of toxic substances as well as important roles in the regenera-
tive processes following traumatic events. In addition to CSF, the
plexus produces various peptides which can have nourishing and
neuroprotective properties.
The choroid plexus is subject to various external factors and
undergoes structural and physiological changes during aging and
disease states. Detrimental changes in the choroid plexus anatomy,
function, and CSF turnover have been found in several neurolog-
ical diseases, including Alzheimer’s disease (AD; Serot et al., 1997,
2000, 2003; Preston, 2001; Stopa et al., 2001; Emerich et al., 2004;
Alvira-Botero and Carro, 2010). In the present review we present
and summarize the recent ﬁndings on pathogenic processes occur-
ring within the choroid plexus and discuss their direct and indirect
effects on the mechanisms of AD.
CHOROID PLEXUS IN AD PATIENTS
Alzheimer’s disease is characterized by the production and accu-
mulation of β-amyloid (Aβ) species in the form of oligomers,
ﬁbrils, and large aggregates called Aβ deposits leading to classi-
cal senile plaques in the brain, and vascular deposits (amyloid
angiopathy) in brain and meningeal blood vessels (Gentile et al.,
2004). Recent advances have led to a better understanding of the
cellular andmolecular pathways of AD. Although amyloid cascade
theory as the primary cause of the disease is actually a contro-
versy, pathological mechanisms in this cascade involve neurotoxic
effects of amyloid peptides probably producing oxidative damage
and apoptosis in brain cells, including choroid plexus epithelial
cells (Perez-Gracia et al., 2009;Vargas et al., 2010b).However, there
are alternative proposed processes or hypotheses which might be
involved in pathological development of AD.
Recently, emphasis has focused on comorbidity of AD and the
deﬁcient clearance of Aβ across the blood–brain barrier (BBB;
Deane et al., 2004; Tanzi et al., 2004; Zlokovic, 2004) and the
blood–CSF barrier (BCSFB; Zlokovic et al., 1996). The traditional
role ascribed to the choroid plexus has been to provide physical
protection to the brain and to facilitate removal of brain metabo-
lites through bulk drainage of CSF.However, recent studies suggest
that the choroid plexus–CSF system plays a muchmore active role
in AD (Weller, 1998; Stopa et al., 2001; Carro et al., 2006; Maurizi,
2010; Vargas et al., 2010b).
The choroid plexus is subject to morphological and physio-
logical changes that produce a wide range of effects. In AD the
choroid plexus develops abnormalities similar to those observed
with aging, although greatly enhanced. Epithelial atrophy is signif-
icantly accentuated: a decrease in cell height is observed compared
to age-matched controls (Serot et al., 2000). Epithelial cells acquire
numerous lipofuscin vacuoles and Biondi bodies increase signif-
icantly in AD patients (Miklossy et al., 1998; Wen et al., 1999;
Alvira-Botero and Carro, 2010). These modiﬁcations could alter
choroid plexus functions, including synthesis, secretion,and trans-
port of proteins and other molecules. Although this is not enough
to cause amyloid deposits in the majority of AD cases, the authors
consider the condition of the choroid plexus an important factor
in the initiation and development of AD pathology. Moreover, the
authors hypothesize that disrupted choroid plexus functions may
precede several AD hallmarks, including amyloid brain accumu-
lation. In the authors’ view, altered choroid plexus functions may
be, at least, one of the primary pathogenic events in late-onset AD
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(Figure 1). Multifactorial changes, including genetic and environ-
mental alterations, result in a number of common mechanisms
of degeneration, such as mitochondrial dysfunction, oxidative
stress, calcium homeostasis dysregulation, and a global decrease
of functional choroid plexus.
Aβ DEPOSITS
The appearance of neuroﬁbrillary tangles and extracellular senile
plaque deposition, whose major constituent is Aβ, are the main
hallmarks of AD (Selkoe, 2000a,b). Besides accumulating in brain
parenchyma and blood vessels, Aβ also accumulates in choroid
plexus (Dietrich et al., 2008). Several data have shown pathological
argyrophilic ﬁlaments with histochemical properties of amyloid
showing striking morphological similarity to curly ﬁbers and/or
tangles accumulating in epithelial cells of choroid plexus (Reusche,
1997; Miklossy et al., 1998, 1999; Wen et al., 1999). Recent results
fromour group revealed the presence of Aβ deposits in the choroid
plexus in autopsy material from AD patients, and suggest a direct
relationship betweenAβdeposits at choroid plexus epitheliumand
the development of a functional and structural disruption of the
organ (Dietrich et al., 2008).
Soluble Aβ, a product of the secretory pathway in amyloid pre-
cursor protein (APP)processing, is producedby the choroidplexus
as observed in both rat and human post-mortem tissue (Kalaria
et al., 1996). APP is synthesized also by many cells outside the
CNS and deposition of Aβ protein was reported to occur in non-
neuronal tissues (Biewend et al., 2006). As shown in Figure 2,
Aβ immunoreactivity is detected in choroid plexus epithelial cells
from non-demented subjects, but the proportion of epithelial cells
containing Aβ accumulation increases signiﬁcantly in choroid
plexus from AD patients (Figure 2). The authors suggest that
Aβ probably accumulates in the choroid plexus secondary to a
dysfunction and a pathological cascade as illustrated in Figure 1.
FIGURE 1 | Proposed sequence of pathological processes involved in
Alzheimer’s disease. Various pathogenic processes contribute to the
dysfunction of the choroid plexus which results in impaired Aβ processing.
This and the resultant accumulation of Aβ can in turn feed back to enhance
the pathogenic processes.
The deﬁcits in mitochondrial activity, increase in oxidative
stress together with above mentioned morphological changes
which are observed in AD, are likely to lead not only to abnormal
brainAβ clearance at the BCSFB, but also increased or defectiveAβ
processing from APP, which has been described in choroid plexus
(Kalaria et al., 1996; Premkumar and Kalaria, 1996) and would
contribute to the development of Aβ accumulation in this tissue.
MITOCHONDRIAL ACTIVITY
Mitochondrial dysfunction is one of the earliest deﬁcits identiﬁed
in AD brains (Valla et al., 2001; Beal, 2005; Manczak et al., 2006).
It has been described that mitochondrial enzyme activity defects
occur in hippocampal neurons and choroidal epithelial cells more
frequently in AD patients (Cottrell et al., 2001). Increase in the
number of COX-deﬁcient choroid epithelial cells provides strong
evidence that a substantial mitochondrial enzyme activity decline
occurs in individual cells more frequently in AD than in normal
aging, This deﬁciency in mitochondrial enzyme activity is likely to
result in a decrease in transport across the epithelial calls and thus
has implications in choroidal Aβ clearance, highlighting the role
of mitochondria in the pathogenesis of AD.
On the other hand, several studies indicate that Aβ itself can
impair mitochondrial function (Canevari et al., 1999; Casley et al.,
2002a,b). Since Aβ deposits accumulate in the choroid plexus of
AD patients (Dietrich et al., 2008), it is likely that Aβ interferes
with their function. In a recent study, we have shown that mito-
chondrial dysfunction in choroid plexus from AD subjects occurs
through a down-regulation of mitochondrial proteins and activ-
ity (Vargas et al., 2010b). In this study, the authors observed a
decrease in cytochrome c oxidase activity in the choroid plexus of
AD patients. The in vitro analysis carried out in choroid plexus
epithelial cells revealed a reduction in the activity of respiratory
chain complex I and IV directly caused by Aβ exposure (Vargas
et al., 2010b).
OXIDATIVE STRESS AND CELL DEATH
Oxidative damage to proteins is a relative early phenomenon in
the pathogenesis of AD. A number of oxidatively damaged pro-
teins have been reported in the hippocampus and inferior parietal
lobules of cases with mild cognitive impairment and AD-related
pathology corresponding to Braak stages III, IV, and V (Butter-
ﬁeld et al., 2006; Reed et al., 2008). In the choroid plexus on the
FIGURE 2 | Aβ deposits (arrows) detected in choroid plexus fromAD
patients. (A) Choroid plexus tissue from age-matched control patient; (B)
Choroid plexus from an AD patient. (B1,B2) High magniﬁcation of the Aβ
deposits from AD patients. Scale bar=20μm, n =3 per group, ≤10 ﬁelds
observed from each sample.
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other hand, oxidative protein damage occurs at later stages of AD
than in other brain areas (Perez-Gracia et al., 2009). The proteins
affected by oxidation in the choroid plexus were found to be 14-
3-3, tropomyosin, and apolipoprotein A-II. Such oxidation may
result in impaired protein interactions, protein folding and pro-
tein kinase activity, abnormal function of endothelial and vascular
smooth muscle cells, and impaired HDL cholesterol metabolism,
thus having important implications in the deterioration of the
functions of the plexus (Perez-Gracia et al., 2009).
Abnormal patterns of stress protein expression are found in the
cerebral cortex and hippocampus of AD subjects (Anthony et al.,
2003). A decreased HO-1 immunoreactivity has been observed
in the AD choroid plexus, in agreement with suppressed HO-1
protein levels in AD CSF (Schipper et al., 2000; Anthony et al.,
2003). Heat shock protein (HSP) 90, a steroid receptor chaperone,
was up-regulated in the AD choroid plexus relative to controls,
and there was a trend toward an increased expression of HSP60,
a mitochondrial stress protein. This is in agreement with mito-
chondrial pathology recently documented in AD choroid plexus
(Cottrell et al., 2001; Vargas et al., 2010b).
In a recent study from our group, we have described an
increased nitric oxide (NO) production by the choroid plexus of
AD patients, associated with Aβ deposits (Vargas et al., 2010b). A
similar situation was observed in the choroid plexus of 12-month-
old APP/PS1 mice, which had a noticeably high Aβ expression.
Excessive generation of NO has been implicated in the patho-
genesis of AD (Smith et al., 1997; Aliyev et al., 2004), and plays
an important role in Aβ-induced mitochondrial dysfunction (Keil
et al., 2004). The interaction between NO and cytochrome c oxi-
dase controls mitochondrial production of hydrogen peroxide,
which has been shown to be implicated in cellular redox signaling
(Galli et al., 2003;Carreras et al., 2004). These results, togetherwith
previous ﬁndings (Veereshwarayya et al., 2006; Petrosillo et al.,
2007), support the hypothesis that Aβ interferes with oxidative
phosphorylation, which results in oxidative stress, and demon-
strate that reactive oxygen species (ROS) generation is secondary
to mitochondrial damage.
The authors also suggest that Aβ is involved in cell death path-
way in choroid plexus since results from our group showed that
Aβ-treated choroid plexus epithelial cells have an increased expres-
sion of caspases 3 and 9 (Vargas et al., 2010b). This ﬁnding is
consistent with another study, where APP transfected cells showed
a signiﬁcant increase in the expression and activity of caspases 3
and 9 (Marques et al., 2003). These data suggest that the exces-
sive generation of ROS would be responsible for initiating the
apoptotic cell death process by up-regulating caspase signaling, as
previously demonstrated (Takuma et al., 2005; Zhu et al., 2006).
PROTEIN EXPRESSION, SYNTHESIS, AND SECRETION
The structure and location of the choroid plexus allows it for the
distribution of molecules throughout the CSF and to the brain
parenchyma as well as locally. This ventricular structure possesses
a multitude of speciﬁc transporters and receptors and many bio-
logically active compounds are produced at the choroid plexus,
including a large number of neuropeptides, growth factors, and
cytokines (Stopa et al., 2001; Alvira-Botero and Carro, 2010).
The above characteristics allow the plexus to exert a ﬁne con-
trol over the CNS extracellular ﬂuid, responding to changes, and
maintaining baseline levels (Stopa et al., 2001).
Within the list of choroid plexus related proteins, the expres-
sion of a vast range of them is signiﬁcantly diminished in AD,
including vascular endothelial growth factor (VEGF; Spuch et al.,
2010), transthyretin (Sousa et al., 2007; Dietrich et al., 2008), gel-
solin (Vargas et al., 2010a), apolipoprotein J (Carro et al., 2006).
TTR, gelsolin andApoJ bind brainAβ, and are involved in its clear-
ance via the endocytotic receptor megalin (Zlokovic et al., 1996;
Chauhan et al., 1999; Carro et al., 2002; Antequera et al., 2009).
It has also been observed that megalin expression is reduced in
the choroid plexus in APP/Ps1 mice and AD patients (Dietrich
et al., 2008). We suggest that Aβ accumulation in the choroid
plexus could disturb megalin-mediated transport and protein
synthesis.
As previously reported, the choroid plexus regulates the
transport of many growth factors, including brain-derived neu-
rotrophic factor (BDNF), nerve growth factor (NGF), VEGF,
insulin, and insulin-like growth factor (IGF-I). In the case of
IGF-I, megalin is involved in IGF-I transport from blood into
the brain, and a decrease in megalin would result in low IGF-
I input to the brain (Carro et al., 2005). As a consequence, the
potential protective roles of IGF-I in AD would be compromised,
includingmodulation of Aβ clearance, brain amyloid content, and
neuroprotection against Aβ toxicity (Carro and Torres-Aleman,
2004).
CONCLUSION
In this review we have proposed that choroid plexus dysfunction
can be a major contributing factor to the pathology of AD. Path-
ogenic processes such as mitochondrial activity deﬁcits, oxidative
stress, and morphological structural changes contribute to the
decreased efﬁcacy of the choroid plexus in clearing of Aβ, thus
resulting in an Aβ accumulation in the brain. This in turn induces
further pathological cascades of toxicity, inﬂammation, and neu-
rodegeneration and may feedback to further enhance the disease
process.
To date, the therapeutic targets have focused on diminishing
the Aβ burden. However, we propose that targeting the upstream
events such as mitochondrial deﬁcits and oxidative stress as well as
the choroid plexus carrier proteins (megalin, gelsolin) may prove
to be more effective. Also, given that the choroid plexus itself has
the ability to produce a nutritive “cocktail” of neurotrophic fac-
tors, there is evidence indicating that transplanted choroid plexus
epithelial cells may potentially be used to protect neurons from
excitotoxic damage (Emerich et al., 2004, 2005; Borlongan et al.,
2008; Thanos et al., 2010).
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